Topical beclomethasone in the therapy of smelling disorders-a new application technique.
Systemic corticosteroid is the first-line-treatment for olfactory dysfunction of sinonasal origin but is afflicted with many side-effects. Topic corticosteroid does not reach the same efficacy but has a remarkable safety profile. In this trial we investigated the efficacy of topic therapy with beclomethasone (BDP) -spray. The drug was applied precisely to the olfactory cleft by a special spraying top-part. In addition we determined extinction and volume of a gelaspon sponge placed in the olfactory cleft to show the difference of the topical spray application. 18 patients with anosmia or hyposmia of different genesis and duration applied BDP-spray twice daily for four weeks. The olfactory function was determined using the TDI score ('Sniffin'-Sticks test battery'). Factors correlated with therapy efficacy were assessed. The median TDI score increased from 13.5 (0-25) at the beginning to 18.5 (1-26) after therapy of four weeks (P = 0.005). The extinction and volume in the moistened sponge was more than two times greater with the top-part than without. The direct application of BDP-spray to the olfactory cleft attained superior therapeutic effects than a usual applied mometasone spray, but did not perform as good as systemic corticosteroid treatment.
Department of Otorhinolaryngology, Head and Neck Surgery, Consultation Service for Olfactory Disorders, Charité, University of Berlin, Charité Campus Mitte Charitéplatz 1, 10117 Berlin, Germany.
Franca
F
Fleiner
Onder
O
Goktas